There is no single test to determine if someone has ADHD; instead, a comprehensive evaluation is required. This evaluation may include a physical examination, psychological testing, review of school and medical records, as well as parent- and teacher-related behavior scales and family interviews.
Although there is no cure for ADHD, there are accepted treatments that help reduce symptoms. Treatments include educational approaches, behavioral modification, and/or stimulant or nonstimulant medication.
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely
|SOURCE Shire plc|
Copyright©2010 PR Newswire.
All rights reserved